Organogenesis Holdings ( (ORGO) ) has released its Q1 earnings. Here is a breakdown of the information Organogenesis Holdings presented to its investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Organogenesis Holdings Inc. is a regenerative medicine company specializing in the development, manufacture, and commercialization of products for the advanced wound care and surgical & sports medicine markets.
In its first quarter of 2025 financial results, Organogenesis Holdings reported a net revenue of $86.7 million, marking a 21% decrease from the previous year. The company experienced a significant net loss of $18.8 million, a stark contrast to the $2.1 million net loss reported in the same quarter of 2024.
The decline in revenue was primarily driven by a 23% decrease in sales of Advanced Wound Care products, although this was partially offset by an 11% increase in sales of Surgical & Sports Medicine products. Operating expenses rose by 5%, and the company recorded a substantial operating loss of $26.7 million compared to the previous year’s $3.9 million.
Despite these challenges, Organogenesis remains optimistic about its future prospects. The company is progressing with its ReNu development plan and expects to submit a Biologics License Application by the end of 2025. Management is confident in navigating the evolving reimbursement landscape and executing its commercial strategy for the remainder of the year.